Physician profile
Adam Evans
NPI 1417101411
$20,900.73
in general payments reported to CMS, 2019-2025
11 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,228 · 2021: $22.25 · 2022: $171 · 2023: $140 · 2024: $90.06 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $901 · Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $901.46 |
| Food and Beverage | $821.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $18,983.90 | 2019-2020 | |
| Abbott Laboratories | $1,102.79 | 2025 | Triclip, Mitraclip |
| Atricure, INC. | $212.28 | 2025 | Synergy Ablation System, Atricure Cryoice Cryosphere Cryoablation System |
| Abiomed | $127.05 | 2025 | |
| Amgen INC. | $120.00 | 2023 | Repatha |
| Alexion Pharmaceuticals, INC. | $112.14 | 2022 | |
| Edwards Lifesciences Corporation | $75.11 | 2022-2025 | Pascal |
| Kerecis Limited | $55.33 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Chiesi USA, INC. | $34.10 | 2023-2025 | Cleviprex |
| Merck Sharp & Dohme LLC | $19.46 | 2024 | Bridion |
| Pacira Pharmaceuticals Incorporated | $15.27 | 2024 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.